• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Double trouble: impact of inappropriate use of asthma medication on the use of health care resources.双重麻烦:哮喘药物使用不当对医疗资源利用的影响
CMAJ. 2001 Mar 6;164(5):625-31.
2
Inappropriate use of inhaled short acting beta-agonists and its association with patient health status.吸入性短效β受体激动剂的不当使用及其与患者健康状况的关联。
Curr Med Res Opin. 2006 Jan;22(1):33-40. doi: 10.1185/030079905X74934.
3
Association between previous health care use and initiation of inhaled corticosteroid and long-acting beta2-adrenergic agonist combination therapy among US patients with asthma.美国哮喘患者中既往医疗保健使用与吸入皮质类固醇和长效β2-肾上腺素能激动剂联合治疗起始的相关性。
Clin Ther. 2009 Nov;31(11):2574-83. doi: 10.1016/j.clinthera.2009.11.007.
4
High use of health services in patients with suboptimal asthma drug regimens: a population-based assessment in British Columbia, Canada.在加拿大不列颠哥伦比亚省,药物治疗方案不充分的哮喘患者对卫生服务的高利用率:一项基于人群的评估。
Pharmacoepidemiol Drug Saf. 2013 Jul;22(7):744-51. doi: 10.1002/pds.3444. Epub 2013 Apr 5.
5
Intervention to reduce unnecessary dispensing of short-acting {beta}-agonists in patients with asthma.干预措施以减少哮喘患者中不必要的短效 {beta}-激动剂的配给。
Ann Pharmacother. 2010 Apr;44(4):623-9. doi: 10.1345/aph.1M697. Epub 2010 Mar 16.
6
Appropriate use of inhaled corticosteroid and long-acting beta(2)-adrenergic agonist combination therapy among asthma patients in a US commercially insured population.美国商业保险人群中哮喘患者吸入性糖皮质激素与长效β2肾上腺素能激动剂联合疗法的合理使用情况
Curr Med Res Opin. 2009 Sep;25(9):2251-8. doi: 10.1185/03007990903155915.
7
Drug utilization and asthma control among young Danish adults with asthma. Analyses of trends and determinants.丹麦年轻哮喘成年人的药物使用与哮喘控制。趋势及决定因素分析。
Dan Med J. 2012 Aug;59(8):B4501.
8
Application of multicategory exposure marginal structural models to investigate the association between long-acting beta-agonists and prescribing of oral corticosteroids for asthma exacerbations in the Clinical Practice Research Datalink.应用多类别暴露边际结构模型,在临床实践研究数据链中探究长效β受体激动剂与哮喘急性加重期口服糖皮质激素处方之间的关联。
Value Health. 2015 Mar;18(2):260-70. doi: 10.1016/j.jval.2014.11.007. Epub 2015 Jan 22.
9
Cross-sectional analysis of the relationship between national guideline recommended asthma drug therapy and emergency/hospital use within a managed care population.对管理式医疗人群中,国家指南推荐的哮喘药物治疗与急诊/住院治疗之间关系的横断面分析。
Ann Allergy Asthma Immunol. 1998 Oct;81(4):327-30. doi: 10.1016/S1081-1206(10)63124-9.
10
Controversies involving inhaled beta-agonists and inhaled corticosteroids in the treatment of asthma.吸入性β受体激动剂和吸入性糖皮质激素在哮喘治疗中的争议。
Clin Chest Med. 1995 Dec;16(4):715-33.

引用本文的文献

1
The Asthma App as a New Way to Promote Responsible Short-Acting Beta2-Agonist Use in People With Asthma: Results of a Mixed Methods Pilot Study.哮喘应用程序作为促进哮喘患者负责任地使用短效β2-激动剂的新方法:一项混合方法试点研究的结果。
JMIR Hum Factors. 2024 Apr 4;11:e54386. doi: 10.2196/54386.
2
Short-acting β-agonist prescription patterns for asthma management in the SABINA III primary care cohort.SABINA III 初级保健队列中用于哮喘管理的短效 β-激动剂处方模式。
NPJ Prim Care Respir Med. 2022 Sep 29;32(1):37. doi: 10.1038/s41533-022-00295-7.
3
Developing a Smartphone Application That Promotes Responsible Short-Acting Beta2-Agonist Use in People with Asthma: A Participatory Design.开发一款促进哮喘患者负责任使用短效β2-激动剂的智能手机应用程序:一项参与式设计。
Int J Environ Res Public Health. 2022 Jul 12;19(14):8496. doi: 10.3390/ijerph19148496.
4
SABA Overuse in Russia - Burden and Possible Causes: An Analysis of the Russian Population in the SABINA III (SABA use IN Asthma) Study.俄罗斯沙丁胺醇过度使用——负担及可能原因:对SABINA III(哮喘患者中沙丁胺醇的使用)研究中俄罗斯人群的分析
J Asthma Allergy. 2022 Mar 24;15:371-379. doi: 10.2147/JAA.S350393. eCollection 2022.
5
Real-world Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Newly Treated Korean Patients With Asthma: A Retrospective Cohort Study.韩国哮喘新确诊患者的真实世界治疗模式、结局及医疗资源利用情况:一项回顾性队列研究
Allergy Asthma Immunol Res. 2022 Mar;14(2):220-232. doi: 10.4168/aair.2022.14.2.220.
6
Short-Acting Beta2-Agonist Use in Asthma in Korea: A 10-Year Population-Based Study.韩国哮喘患者使用短效β2受体激动剂情况:一项基于人群的10年研究。
Allergy Asthma Immunol Res. 2021 Nov;13(6):945-953. doi: 10.4168/aair.2021.13.6.945.
7
The cost-effectiveness of as-needed budesonide-formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in Canada.按需使用布地奈德-福莫特罗与低剂量吸入性糖皮质激素维持治疗对加拿大轻度哮喘患者的成本效益分析
Allergy Asthma Clin Immunol. 2021 Oct 12;17(1):108. doi: 10.1186/s13223-021-00610-w.
8
High Use of SABAs is Associated with Higher Exacerbation Rate in Dutch Patients with Asthma.在荷兰哮喘患者中,高剂量使用短效β2激动剂(SABAs)与更高的急性加重率相关。
J Asthma Allergy. 2021 Jul 12;14:851-861. doi: 10.2147/JAA.S292943. eCollection 2021.
9
Observational studies assessing the pharmacological treatment of obstructive lung disease: strengths, challenges and considerations for study design.评估阻塞性肺疾病药物治疗的观察性研究:研究设计的优势、挑战及注意事项
ERJ Open Res. 2020 Oct 13;6(4). doi: 10.1183/23120541.00044-2020. eCollection 2020 Oct.
10
Contributing Factors for Underutilization of Inhaled Corticosteroids Among Asthmatic Patients Attending at Adama Hospital Medical College, Adama, Ethiopia.埃塞俄比亚阿达马阿达马医院医学院哮喘患者吸入性糖皮质激素使用不足的影响因素
J Asthma Allergy. 2020 Sep 11;13:333-341. doi: 10.2147/JAA.S264119. eCollection 2020.

本文引用的文献

1
Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.《1999年加拿大哮喘共识报告》。加拿大哮喘共识小组。
CMAJ. 1999 Nov 30;161(11 Suppl):S1-61.
2
beta2-Adrenergic receptor haplotypes in mild, moderate and fatal/near fatal asthma.轻度、中度及致死性/近致死性哮喘中的β2-肾上腺素能受体单倍型
Am J Respir Crit Care Med. 1998 Sep;158(3):787-91. doi: 10.1164/ajrccm.158.3.9801035.
3
Social deprivation and asthma.社会剥夺与哮喘
Respir Med. 1997 Nov;91(10):603-8. doi: 10.1016/s0954-6111(97)90006-8.
4
Socio-economic disadvantage, quality of medical care and admission for acute severe asthma.社会经济劣势、医疗质量与急性重症哮喘的入院治疗
Aust N Z J Med. 1997 Jun;27(3):294-300. doi: 10.1111/j.1445-5994.1997.tb01981.x.
5
Income level and asthma prevalence and care patterns.收入水平与哮喘患病率及护理模式。
Am J Respir Crit Care Med. 1997 Mar;155(3):1060-5. doi: 10.1164/ajrccm.155.3.9116987.
6
Profile of children requiring emergency treatment for asthma.需要哮喘急诊治疗的儿童概况。
Ann Allergy Asthma Immunol. 1997 Feb;78(2):221-4. doi: 10.1016/S1081-1206(10)63391-1.
7
Factors associated with emergency department dependence of patients with asthma.哮喘患者急诊科依赖相关因素。
Chest. 1997 Feb;111(2):290-5. doi: 10.1378/chest.111.2.290.
8
The association between asthma drugs and severe life-threatening attacks.哮喘药物与严重危及生命的发作之间的关联。
Chest. 1996 Dec;110(6):1446-51. doi: 10.1378/chest.110.6.1446.
9
A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists.哮喘患者超额死亡率及吸入性β受体激动剂使用情况的队列分析。
Am J Respir Crit Care Med. 1994 Mar;149(3 Pt 1):604-10. doi: 10.1164/ajrccm.149.3.8118625.
10
Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity?吸入性β-受体激动剂的使用与因严重程度混淆导致的危及生命的哮喘之间是否存在关联?
Am Rev Respir Dis. 1993 Jul;148(1):75-9. doi: 10.1164/ajrccm/148.1.75.

双重麻烦:哮喘药物使用不当对医疗资源利用的影响

Double trouble: impact of inappropriate use of asthma medication on the use of health care resources.

作者信息

Anis A H, Lynd L D, Wang X H, King G, Spinelli J J, Fitzgerald M, Bai T, Paré P

机构信息

Centre for Health Evaluation and Outcome Sciences, St. Paul's Hospital, Vancouver, BC.

出版信息

CMAJ. 2001 Mar 6;164(5):625-31.

PMID:11258208
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC80815/
Abstract

BACKGROUND

There is considerable controversy about the regular use of short-acting beta-agonists for the treatment of asthma. Although case-control studies have suggested that excessive use of these drugs may worsen asthma control and increase the risk of fatal or near-fatal asthma, the controversy remains unresolved because of the confounding that exists among disease control, disease severity and the use of short-acting beta-agonists. Whatever the cause-and-effect relation between the use of short-acting beta-agonists and disease severity, we hypothesized that their excessive use, in conjunction with underuse of inhaled corticosteroids, would be a marker for poorly controlled asthma and excessive use of health care resources.

METHODS

To characterize the pattern of health services utilization among asthmatic patients taking various doses of inhaled beta-agonists and corticosteroids in British Columbia, we linked the relevant health administrative databases. All patients between 5 and 50 years of age for whom a prescription for a short-acting beta-agonist was filled in 1995 and whose prescription data were captured through the provincial drug plan were included in a retrospective analysis of prescriptions for asthma drugs, physician prescribing patterns and health services utilization. Patients' use of asthma medication was classified as appropriate (low doses of short-acting beta-agonist and high doses of inhaled corticosteroid) or inappropriate (high doses of short-acting beta-agonist and low doses of inhaled corticosteroid), and the 2 resulting groups were compared, by means of logistic, Poisson and gamma regression, for differences in prescribing patterns, physician visits and use of hospital resources.

RESULTS

A total of 23,986 patients were identified as having filled a prescription for a short-acting beta-agonist (for inhalation) in 1995. Of these, 3069 (12.8%) filled prescriptions for 9 or more canisters of beta-agonist, and of this group of high-dose beta-agonist users, 763 (24.9%) used no more than 100 micrograms/day of inhaled beclomethasone. On average, those with inappropriate use of beta-agonists visited significantly more physicians for their prescriptions (1.8 v. 1.4), and each of these physicians on average wrote significantly more prescriptions for asthma medications per patient than the physicians who prescribed to appropriate users (5.2 v. 2.5 prescriptions). Patients with inappropriate use were more likely to be admitted to hospital (adjusted relative risk [RR] 1.68, 95% confidence interval [CI] 1.25-2.26), were admitted to hospital more frequently (adjusted RR 1.81, 95% CI 1.41-2.32) and were more likely to require emergency admission (adjusted RR 1.93, 95% CI 1.35-2.77).

INTERPRETATION

Despite the widespread distribution of guidelines for asthma pharmacotherapy, inappropriate use of asthma medications persists (specifically excessive use of inhaled short-acting beta-agonists combined with underuse of inhaled corticosteroids). Not only are patients who use medication inappropriately at higher risk for fatal or near-fatal asthma attacks, but, as shown in this study, they use significantly more health care resources than patients with appropriate medication use.

摘要

背景

对于常规使用短效β受体激动剂治疗哮喘存在相当大的争议。尽管病例对照研究表明过度使用这些药物可能会使哮喘控制恶化并增加致命或近乎致命哮喘的风险,但由于疾病控制、疾病严重程度和短效β受体激动剂使用之间存在混杂因素,这一争议仍未得到解决。无论短效β受体激动剂的使用与疾病严重程度之间的因果关系如何,我们推测过度使用短效β受体激动剂并同时吸入糖皮质激素使用不足,将是哮喘控制不佳和医疗资源过度使用的一个标志。

方法

为了描述不列颠哥伦比亚省服用不同剂量吸入性β受体激动剂和糖皮质激素的哮喘患者的卫生服务利用模式,我们将相关的卫生行政数据库进行了关联。1995年开具短效β受体激动剂处方且处方数据通过省级药物计划获取的所有5至50岁患者,被纳入哮喘药物处方、医生处方模式和卫生服务利用的回顾性分析。患者的哮喘药物使用被分类为适当(低剂量短效β受体激动剂和高剂量吸入性糖皮质激素)或不适当(高剂量短效β受体激动剂和低剂量吸入性糖皮质激素),并通过逻辑回归、泊松回归和伽马回归比较这两组在处方模式、医生就诊次数和医院资源使用方面的差异。

结果

共有23986名患者在1995年被确定开具了短效β受体激动剂(吸入用)处方。其中,3069名(12.8%)患者开具了9罐或更多罐β受体激动剂的处方,在这组高剂量β受体激动剂使用者中,763名(24.9%)患者每天吸入倍氯米松不超过100微克。平均而言,β受体激动剂使用不当的患者因处方看医生的次数明显更多(1.8次对1.4次),而且这些医生平均为每位患者开具的哮喘药物处方比为适当使用者开处方的医生显著更多(5.2张对2.5张处方)。使用不当的患者更有可能住院(调整后相对风险[RR]为1.68,95%置信区间[CI]为1.25 - 2.26),住院频率更高(调整后RR为1.81,95%CI为1.41 - 2.32),并且更有可能需要急诊入院(调整后RR为1.93,95%CI为1.35 - 2.77)。

解读

尽管哮喘药物治疗指南已广泛传播,但哮喘药物使用不当的情况仍然存在(具体为吸入短效β受体激动剂过度使用且吸入糖皮质激素使用不足)。不仅药物使用不当的患者发生致命或近乎致命哮喘发作的风险更高,而且如本研究所示,他们使用的医疗资源比药物使用适当的患者显著更多。